Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients.

ABSTRACT:

Background

Locally advanced melanoma has a variable prognosis. Currently, there are no reliable criteria to stratify the risk of disease relapse and identify those patients who will benefit the most from adjuvant therapies. Circulating tumor DNA (ctDNA) is an emerging biomarker measuring the presence of tumor-derived DNA in blood.

Patients and methods

We used a bespoke, tumor-informed assay (RaDaR®, NeoGenomics, Inc.) to detect ctDNA in 276 prospectively collected plasma samples from 66 melanoma patients receiving definitive treatment. Collection time points included landmark (after completion of local treatment) and every 3-6 months for up to 2 years.

Results

ctDNA was detected in at least one plasma sample in 19 patients (29%), including 6/65 (9%) at landmark (post-

SUBMITTER: Genta S 

PROVIDER: S-EPMC11615122 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature